Eris Lifesciences Ltd Q1 FY27 Results

Eris Lifesciences opened FY27 with consolidated revenue from operations of ₹873.25 Cr, up 12.97% YoY (₹773.00 Cr) and 15.4% QoQ, and net profit of ₹143.32 Cr (₹142.39 Cr attributable to owners), up 14.56% YoY, at an EPS of ₹10.28. Both topline and bottom line grew in double digits year-on-year, on a clean comparison with no exceptional items on either side.

The headline ~49% QoQ profit drop (versus ₹279.10 Cr in Q4 FY26) is an accounting artifact, not a deterioration. Q4 FY26 carried a ~₹150 Cr deferred-tax credit from remeasurement under the new tax law, which turned that quarter's tax line into a net credit of ₹119.69 Cr and inflated its PAT. This quarter tax normalised to ₹36.17 Cr (~36% effective), so the year-on-year read — where both quarters are clean — is the fair one: +14.6% PAT on +13% revenue.

The stock went into the print at ₹1,393.6, down 2.5% over the past month of trading.

For context: this is the second-highest quarterly PAT of the last 6 quarters; revenue is at a 6-quarter high.

Operating margins softened exactly as management had signalled. EBITDA margin was ~34% versus ~35.8% a year ago (~190 bps compression), and the company's own operating-margin metric slipped to 25.94% from 27.02%. On the May concall management guided a softer H1 FY27 on new-launch expenses with H2 recovery toward ~36% consolidated / 37% domestic-formulations EBITDA margin driven by insourced manufacturing, so this print sits on-track with that outlook rather than surprising it. Net profit margin held roughly flat at 16.41% (vs 16.18%), as lower finance costs (₹46.65 Cr) and normalised tax offset the operating squeeze.